Search
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalbody weight of at least 40 kg. … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[A274641] As a result, obinutuzumab induces greater antibody-dependent cellular cytotoxicity (ADCC) and a higher degree of direct cell death compared to rituximab. … [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab.
Products: GAZYVA 1000 MG IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADETCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalunmet medical need based on a surrogate endpoint. … [L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesCinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia.
Donanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigationalcontribute to the pathophysiology of Alzheimer's Disease (AD). … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that
Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (, Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimerOxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitOxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth … Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index